Last reviewed · How we verify
Biological analyses
This drug targets the PD-1 receptor to modulate the immune system.
This drug targets the PD-1 receptor to modulate the immune system. Used for Non-small cell lung cancer, PD-L1 positive, Melanoma.
At a glance
| Generic name | Biological analyses |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By binding to PD-1, the drug prevents the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Melanoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
Key clinical trials
- Study of Families With Twins or Siblings Discordant for Rheumatic Disorders
- MIMICC Study in Patients With Colorectal Cancer (NA)
- Kaempferol Absorption and Pharmacokinetics Evaluation (NA)
- Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal
- Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study) (NA)
- Tumor Microenvironment Changes After Neoadjuvant Chemo-Immunotherapy in Esophageal Squamous Cell Carcinoma
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biological analyses CI brief — competitive landscape report
- Biological analyses updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI